Immunogenicity of Menactra Vaccine

For US Health-care Professionals Only

Prescribing Information | Safety Information | For Consumers

About Menactra Vaccine
Age Indication
Immunogenicity
Safety
Reimbursement
Menactra Vaccine FAQs

PROVEN IMMUNOGENICITY - DEMONSTRATED IN CLINICAL TRIALS AND IN OVER 6 YEARS OF USE.

Five serogroups, including A, B, C, Y and W-135, are responsible for almost all cases of meningococcal disease worldwide.¹ Menactra vaccine provides protection against invasive meningococcal disease from all 4 vaccine-preventable serogroups (A, C, Y and W-135).

Large comparative trials were conducted in infants 9 through 12 months of age, children 2 through 10 years of age, adolescents 11 through 18 years of age, and adults through 55 years of age to compare the immune responses elicited by Menactra and Menomune^®–A/C/Y/W-135 (Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined) vaccines.¹

The immune responses to Menactra and Menomune^®–A/C/Y/W-135 vaccines were comparable for all 4 serogroups¹:

Among all adolescents, whether seronegative or seropositive pre-vaccination, 82% to 97% achieved a ≥4-fold increase in antibody titers for serogroups A, C, Y and W-135 following administration of Menactra vaccine.¹

Demonstrated Immune Response Following a Single Intramuscular Injection²

Rates of ≥4-fold increase in all subjects in serogroup SBA^a titers after administration of Menactra vaccine (n=425) or the meningococcal polysaccharide vaccine (n=423)²

Important Safety Information
Indication
Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

Safety Information
The most common local and systemic adverse reactions to Menactra vaccine include injection site pain, redness, and induration (all age groups); irritability, crying, drowsiness, loss of appetite, and diarrhea (infants and children); headache, fatigue, and malaise (adolescents and adults). Other adverse reactions may occur.

Menactra vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine. Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. The decision to give Menactra vaccine should take into account the potential benefits and risks. GBS has been reported in temporal relationship following administration of Menactra vaccine. Vaccination with Menactra vaccine may not protect all individuals

Before administering Menactra vaccine, please see accompanying full Prescribing Information.